December 31, 2002
In a clinical study conducted in 783 treatment-nave, HIV-infected individuals Zerit® XR was comparable to the previously approved twice daily formulation of Zerit. In this randomized, controlled study, participants were randomized to either the extended release or standard formulation, in combination with lamivudine and efavirenz. The proportion of patients with HIV-RNA (viral load levels) below 400 copies/mL at 48 weeks was 79% and 76% for the extended release and immediate release-containing regimens, respectively. For viral load under 50, the response rates were 55% and 57% for the new and old formulations, respectively. The tolerability and safety profile of the new once daily, extended release formulation is comparable to that of the previously approved twice daily formulation.
The study results were supported by a second, smaller study in 150 treatment nave patients.
More convenient formulations, such as Zerit XR, may help patients with HIV more readily adhere to treatment regimens.
Zerit XR is a product of the Bristol-Myers Squibb Company.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.